Efficacy of olaparib combined with pembrolizumab in second-line treatment for extensive-stage small cell lung cancer
10.3760/cma.j.cn112152-20200319-00226
- VernacularTitle:奥拉帕尼联合帕博利珠单抗二线治疗广泛期小细胞肺癌的疗效和安全性
- Author:
Zhaozhen WU
1
;
Sujie ZHANG
;
Yi HU
Author Information
1. 南开大学医学院，天津 300071
- Keywords:
Neoplasms, small cell lung;
Olaparib;
Pembrolizumab;
Second-line treatment
- From:
Chinese Journal of Oncology
2020;42(7):590-593
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To compare the efficacy and safety of olaparib in combination with pembrolizumab with pembrolizumab alone in second-line treatment for patients with extensive stage-small cell lung cancer (ES-SCLC) whose ages ranged from 40 to 80 years.Methods:From March 2017 to October 2019, 21 patients with progressed or relapsed small cell lung cancer after standard first line treatment were enrolled in this study. The olaparib/pembrolizumab group ( n=11) was treated by olaparib 300mg twice per day combined with pembrolizumab 200mg once every 3 weeks, while pembrolizumab group was treated by pembrolizumab alone. Results:The objective response rate (ORR) of olaparib/pembrolizumab group and pembrolizumab group were 45.5% and 10.0%, respectively ( P=0.149), and the disease control rate (DCR) were 81.8% and 70.0% ( P=0.635). The median progression-free survival (PFS) were 5.93 months and 3.53 months ( P=0.036), the median overall survival (OS) were 10.43 months and 8.43 months ( P=0.063). The adverse reaction incidences of all grades were 90.9% and 70.0% ( P=0.311), and the incidences of grade Ⅲ-Ⅴ including myelosuppression were 36.4% and 10.0% ( P=0.311), gastrointestinal reaction were 9.1% and 10.0%, ( P=1.000) and other immune-related adverse events were 18.2% and 30.0% ( P=1.000). Further analysis showed the metastatic number ( P=0.006), platinum sensitivity ( P=0.036) and LDH level ( P=0.022) significantly affected the ORR of olaparib/pembrolizumab therapy. Conclusion:Our preliminary study indicates that olaparib combined with pembrolizumab is an efficient and safe second-line treatment therapy for patients with ES-SCLC.
